

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 784 979 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

23.07.1997 Bulletin 1997/30

(51) Int Cl. 5: **A61K 38/17**

// (A61K38/17, 47:10),

(A61K38/17, 47:14)

(21) Application number: **97300299.1**(22) Date of filing: **17.01.1997**

(84) Designated Contracting States:

**AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL
PT SE**

Designated Extension States:

AL LT LV RO SI

• Dodd, Steven Witt

Indianapolis, Indiana 46254 (US)

• Pekar, Allen Howard

Indianapolis, Indiana 46220 (US)

(30) Priority: **07.02.1996 GB 9602408****19.01.1996 US 10229**

(74) Representative: Hudson, Christopher Mark et al

Lilly Industries Limited

European Patent Operations

Erl Wood Manor

Windlesham Surrey GU20 6PH (GB)

(71) Applicant: **ELI LILLY AND COMPANY**

Indianapolis, Indiana 46285 (US)

(72) Inventors:

• Beals, John Michael

Indianapolis, Indiana 46278-1853 (US)

Remarks:

The applicant has subsequently filed a sequence listing and declared, that it includes no new matter.

(54) **Obesity protein formulations**

(57) The present invention discloses a soluble parenteral formulation, comprising obesity protein and

a preservative selected from the group consisting of alkylparaben, chlorobutanol, or a mixture thereof.

BEST AVAILABLE COPY**EP 0 784 979 A2**